Table 4.
Gene expression levels of IFN-related genes in PBMCs stimulated by CpG2216.
| Baseline | 4 Weeks | |||||
|---|---|---|---|---|---|---|
| n | Median (IQR) | n | Median (IQR) | p Value #2 | ||
| IFN-α | Placebo | 44 | 49.6 (14.5–105.7) | 47 | 13.8 (6.1–27.2) | <0.001 |
| MCC1849 | 47 | 42.7 (17.6–178.0) | 48 | 21.7 (11.8–38.3) | <0.001 | |
| p value #1 | 0.237 | 0.026 | ||||
| IFN-β | Placebo | 44 | 66.3 (33.5–140.9) | 47 | 36.2 (14.7–57.2) | <0.001 |
| MCC1849 | 47 | 64.3 (30.6–237.2) | 48 | 49.7 (27.8–82.3) | <0.001 | |
| p value #1 | 0.368 | 0.045 | ||||
| IFN-γ | Placebo | 44 | 3.4 (2.2–6.7) | 47 | 2.7 (1.7–5.4) | 0.062 |
| MCC1849 | 47 | 4.2 (2.3–7.4) | 48 | 4.1 (2.5–6.7) | 0.863 | |
| p value #1 | 0.330 | 0.017 | ||||
p value #1, comparison between groups by the Mann–Whitney U test. p value #2, comparison between baseline and 4 weeks by the Wilcoxon signed-rank sum test.